Allergan, Inc. Spikes On Renewed Interest From Actavis PLC

Allergan, Inc. AGN shares spiked Tuesday on a report of renewed acquisition interest from Actavis plc ACT.

Allergan would consider a bid of greater than $200 per share for its 63.69 million shares outstanding, according to unnamed sources cited by Reuters, which said Actavis may contact Allergan this week.

Allergan reportedly rejected an offer from Actavis last month.

Allergan has sought in recent months to fend off a hostile $53 billion takeover bid from Valeant Pharmaceuticals Intl Inc., backed by Bill Ackman's Pershing Square Capital.

Allergan recently held talks about acquiring Salix Pharmaceuticals Ltd. for more than $10 billion in order to make itself too big and expensive for Valeant. Those talks faltered according to widespread reports.

Allergan traded recently at $187.69, up 2.5 percent.